What comes after sotorasib and adagrasib?

Aakash Desai, Thoracic/Phase 1 Oncologist at UAB O’Neal Comprehensive Cancer Center, shared a post on X about a recent paper titled “The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?” published in Lung Cancer Journal.

Authors: Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi.  .

“KRAS, once ‘undruggable,’ now sotorasib and adagrasib, but efficacy is limited.  

Next-gen KRAS G12C/non-G12Ci and innovative approaches like molecular shielding and protein degradation are on the horizon!  

Combos with SHP2/SOS1 inhibitors, chemo, or immune checkpoint inhibitors are being explored to tackle resistance.
Great review in Lung Cancer Journal.”

Source: Aakash Desai/X